SCHEMBL1266955

SCHEMBL1266955

CCNC(=S)CN

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1755595 0.75
SCHEMBL18160818 0.75 ALDH1A1 (0.39)
SCHEMBL3075815 0.73
SCHEMBL9615264 0.72 EPHX1 (0.46)
SCHEMBL19302719 0.72
SCHEMBL7966730 0.71
SCHEMBL4438063 0.71
Ethylamine SCHEMBL11659087 0.71
SCHEMBL8861968 0.71
SCHEMBL1266953 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140357654-A1 METHODS OF TREATING SCHIZOPHRENIA WITH PHENYLALANINE ENAMIDE DERIVATIVE INHIBITORS OF a4 INTEGRIN POSSESSING A CYCLOBUTENE GROUP AESTUS THERAPEUTICS, INC. (US) 2014-12-04 US disclosed
EP-2775840-A1 METHODS OF TREATING SCHIZOPHRENIA WITH PHENYLALANINE ENAMIDE DERIVATIVE INHIBITORS OF 4 INTEGRIN POSSESSING A CYCLOBUTENE GROUP Aestus Therapeutics, Inc. (US) 2014-09-17 EP disclosed
WO-2013070842-A1 METHODS OF TREATING SCHIZOPHRENIA WITH PHENYLALANINE ENAMIDE DERIVATIVE INHIBITORS OF α4 INTEGRIN POSSESSING A CYCLOBUTENE GROUP AESTUS THERAPEUTICS, INC. (US) 2013-05-16 WO disclosed
US-20110034495-A1 Method of Modulating Stress-Activated Protein Kinase System INTERMUNE, INC. (US) 2011-02-10 US disclosed
US-7786177-B2 Phenylalanine enamide derivatives UCB PHARMA S.A. (BE) 2010-08-31 US disclosed
US-7763729-B2 Bicyclic heteroaromatic derivatives UCB PHARMA S.A. (BE) 2010-07-27 US disclosed
US-7645770-B2 Phenylalanine enamide derivatives UCB PHARMA S.A. (BE) 2010-01-12 US disclosed
US-7592455-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA S.A. (BE) 2009-09-22 US disclosed
US-20090186914-A1 Phenylalanine Enamide Derivatives UCB PHARMA, S.A. (BE) 2009-07-23 US disclosed
US-7557130-B2 Bicyclic heteroaromatic alanines UCB PHARMA, S.A. (BE) 2009-07-07 US disclosed
WO-2000073260-A1 SQUARIC ACID DERIVATIVES AS CELL ADHESION MOLECULES CELLTECH R&D LIMITED (GB) 2000-12-07 WO disclosed
EP-1044215-A1 ANTI-INFLAMMATORY PHENYLALANINE DERIVATIVES CELLTECH THERAPEUTICS LIMITED (GB) 2000-10-18 EP disclosed
US-6110945-A AN ANTIINFLAMMATORY AGENT INHIBITING THE BINDING OF INTEGRINS TO THEIR LIGANDS; IN THE PROPHYLAXIS FOR TREATING IMMUNE OR INFLAMMATORY DISORDERS CELLTECH THERAPEUTICS LIMITED (GB) 2000-08-29 US disclosed
WO-2000031067-A1 PROPANOIC ACID DERIVATIVES AS INTEGRIN INHIBITORS CELLTECH THERAPEUTICS LIMITED (GB) 2000-06-02 WO disclosed
WO-2000020396-A1 PHENYLALKANOIC ACID DERIVATIVES AS INHIBITORS OF ALPHA4 INTEGRINS CELLTECH THERAPEUTICS LIMITED (GB) 2000-04-13 WO disclosed
WO-2000018760-A1 1,3-BENZODIAZEPINES WITH INTEGRIN INHIBITORY ACTIVITY FOR USE IN THE TREATMENT OF INFLAMMATORY DISORDERS CELLTECH THERAPEUTICS LIMITED (GB) 2000-04-06 WO disclosed
WO-2000018759-A1 PHENYLALANINE DERIVATIVES AS ALPHA 4 INTEGRIN INHIBITORS CELLTECH THERAPEUTICS LIMITED (GB) 2000-04-06 WO disclosed
WO-1999035163-A1 PHENYLALANINE DERIVATIVES CELLTECH THERAPEUTICS LIMITED (GB) 1999-07-15 WO disclosed
US-5864043-A CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST KARL THOMAE GMBH (DE) 1999-01-26 US disclosed
US-5541229-A ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS DR. KARL THOMAE GMBH (DE) 1996-07-30 US disclosed